Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD

Primary Objectives:

PART A:

* To prospectively validate biomarkers in risk stratification among stable CHD subjects, i.e. evaluation of the biomarker performance in accurately predicting CV events including CV death, nonfatal MI, HF events * To identify high-risk CHD subjects for the subsequent RCT, i.e. 15-20% of the screened patient population at the highest risk

PART B

• To demonstrate whether a personalised prevention (PPP) strategy in high-risk CHD subjects results in a decreased risk of cardiovascular (CV) events (CV death, nonfatal myocardial infarction (MI) or heart failure (HF) events) as compared to the local usual care (UC)

Secondary Objectives:

* To evaluate the difference between the PPP arm to the UC arm as listed in section outcomes. * To evaluate the health economic value of the PPP * To prospectively study associations (in all enrolled subjects) between separate biomarkers (CERT2, hs-troponin, proBNP, Cystatin C) or their score (CoroPredict)

In addition to the above-listed primary and secondary objectives of the study, the following analysis will be carried out based on the data to be collected during the trial:

* Effect of personalised prevention on behavioural change. * Effect of behavioural change on CV outcomes and blood pressure. * Identification of key components and risk factors affecting effectiveness of the PPP. * Inter-relationship between nutrition and exercise will be evaluated. Nutrition parameters will be based on questionnaires and biomarkers (Trimethylamine N-oxide (TMAO), Trimethyllysine (TML), carnitines and their metabolites). * Effect of the use of the CoroPrevention Tool Suite (EXPERT tool) on the agreement between exercise prescriptions generated by cardiovascular nurses to subjects with CVD, and the ESC guideline-directed exercise prescriptions * Effect of greater adherence to EXPERT tool-driven exercise prescriptions by clinicians and subjects, on CVD risk, physical fitness, and prognosis (hospitalisations, adverse events, mortality) in subjects with CVD. * Effect of the use of the EXPERT tool-driven medication decision support system on the agreement between medication prescriptions generated by cardiovascular nurses to subjects with CVD, and the ESC guideline-directed medication prescriptions * Effect of better adherence by both clinicians and subjects to ESC guideline prescriptions, driven by the medication decision support system within the EXPERT tool, on CVD risk and prognosis (hospitalisations, adverse events, mortality) in subjects with CVD. * Investigation of the user experience and user acceptance of the CoroPrevention Tool Suite.

• To evaluate the difference between PPP arm to the UC arm in [Срок оценки: 3 years follow-up]
• To evaluate the difference between PPP arm to the UC arm in [Срок оценки: 3 years follow-up]
• To evaluate the difference between PPP arm to the UC arm in [Срок оценки: 3 years follow-up]
• To evaluate the difference between PPP arm to the UC arm in [Срок оценки: 3 years follow-up]
• To evaluate the difference between PPP arm to the UC arm in [Срок оценки: 3 years follow-up]
• To evaluate the health economic value of the PPP [Срок оценки: 3 years follow-up]
• • To prospectively study associations (in all enrolled subjects) between separate risk biomarkers (CERT2, hs-troponin , proBNP, Cystatin C) or their score (CoroPredict) and [Срок оценки: 3 years follow-up]